

Page 32, please change the Abstract as follows:

---ABSTRACT

B1 A method for treating or preventing atherosclerosis in a mammal is described. An antibody for inhibiting the interaction between P-selectin and a ligand of P-selectin and between E-selectin and a ligand of E-selectin is provided. The antibody is administered to a mammal in need of such treatment to cause this inhibition to occur.---

IN THE CLAIMS:

Please cancel claims 53-60, 70, 75, 80-82, 84-86 and 88 without prejudice.

B2 39. (Amended) A method for treating or inhibiting atherosclerosis in a mammal comprising:
providing a P-selectin antibody for inhibiting an interaction between P-selectin and a ligand of P-selectin, and between E-selectin and a ligand of E-selectin; and
administering said antibody to a mammal in need of such treatment so as to cause such inhibition to occur.

40. (Amended) The method of claim 39 wherein said antibody is administered to the mammal in conjunction with a vessel-corrective technique.

B3 61. (Amended) The method of claim 39 wherein said antibody is an inhibitor of a molecule required for the synthesis, post-translational modification or functioning of said P-selectin or said ligand of P-selectin.

62. (Amended) The method of claim 39 wherein said antibody inhibits interaction between said P-selectin and said ligand of P-selectin or between E-selectin and said ligand of E-selectin so as to inhibit formation of an atherosclerotic streak, or reverse a formed atherosclerotic fatty streak.

63. (Amended) The method of claim 39 wherein said antibody inhibits interaction between said P-selectin and said ligand of P-selectin or between E-selectin and said ligand of E-selectin so as to inhibit formation of an atherosclerotic intermediate lesion, or reverse a formed atherosclerotic intermediate lesion.

B3 64. (Amended) The method of claim 39 wherein said antibody inhibits interaction between said P-selectin and said ligand of P-selectin or between said E-selectin and said ligand of E-selectin so as to inhibit formation of an atherosclerotic fibrous plaque, or reverse a formed atherosclerotic fibrous plaque.

65. (Amended) The method of claim 39 wherein said antibody inhibits interaction between said P-selectin and said ligand of P-selectin or between said E-selectin and said ligand of E-selectin so as to inhibit formation of an atherosclerotic lesion after a surgical procedure for inhibiting restenosis.

B4 69. (Amended) A therapeutic agent in a dosage form and concentration suitable for treating or inhibiting atherosclerosis in a mammal in need of such treatment, said agent being effective to inhibit interaction between P-selectin and a ligand of P-selectin and between E-selectin and a ligand of E-selectin, wherein said therapeutic agent is a P-selectin antibody.

71. (Amended) The method of claim 39, wherein said antibody is administered at a dose of about 0.01 to about 200 mg/kg body weight.

72. (Amended) The method of claim 39, wherein said antibody is administered at a dose of about 1 to about 100 mg/kg body weight.

B5 73. (Amended) The method of claim 39, wherein said antibody further inhibits interaction between L-selectin and a ligand of L-selectin.

74. (Amended) A method for treating or inhibiting atherosclerosis in a mammal, comprising:

B5 providing a P-selectin antibody for inhibiting interaction between P-selectin and a ligand of P-selectin and between L-selectin and a ligand of L-selectin; and
administering said antibody to a mammal in need of such treatment so as to cause such inhibition to occur.

76. (Amended) The method of claim 39, wherein said antibody is administered in sequential exposures over a period of hours, days, weeks, months or years.

B6 77. (Amended) The method of claim 39, wherein said antibody is administered repeatedly, or by controlled release delivery system.

78. (Amended) The method of claim 39, wherein the antibody is administered in combination with other therapeutic agents.

79. (Amended) The method of claim 39, wherein the antibody is administered as a pill, as an injection or as an implant.

REMARKS

The Title of the invention and the Abstract have now been amended in order to conform more closely to the presently claimed invention as suggested by the Examiner. The typographical error in claim 65 has also been corrected.

Claims 62-64 have been rejected under 35 U.S.C. §112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the invention. In particular, the Examiner states that the expression "at least partially" renders the claims indefinite.

The claims have now been amended in order to delete the objectionable language. Antecedent support for the amendment is found on page 4, lines 12-18 of the specification. This amendment is not intended to limit the scope of the claims which are intended to cover less than complete inhibition and less than complete reversal of the condition (atherosclerosis).